PMV Pharmaceuticals/PMVP

$1.79

9.49%
-
1D1W1MYTD1YMAX

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.

Ticker

PMVP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Mack

Employees

63

Headquarters

Princeton, United States

PMVP Metrics

BasicAdvanced
$92.08M
Market cap
-
P/E ratio
-$1.44
EPS
1.59
Beta
-
Dividend rate
$92.08M
1.59026
$9.72
$1.18
576K
14.784
-26.4%
-29.24%
-27.72%
0.408
0.408
10.18%

What the Analysts think about PMVP

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
388.83% upside
High $18.00
Low $5.00
$1.79
Current price
$8.75
Average price target

PMVP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-15.7M
-5.42%
Profit margin
0%
-

PMVP Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 19.69%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.42
-$0.38
-$0.34
-$0.31
-
Expected
-$0.46
-$0.48
-$0.45
-$0.39
-$0.37
Surprise
-8.36%
-20%
-23.77%
-19.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for PMV Pharmaceuticals stock?

PMV Pharmaceuticals (PMVP) has a market cap of $92.08M as of April 15, 2024.

What is the P/E ratio for PMV Pharmaceuticals stock?

The price to earnings (P/E) ratio for PMV Pharmaceuticals (PMVP) stock is 0 as of April 15, 2024.

Does PMV Pharmaceuticals stock pay dividends?

No, PMV Pharmaceuticals (PMVP) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next PMV Pharmaceuticals dividend payment date?

PMV Pharmaceuticals (PMVP) stock does not pay dividends to its shareholders.

What is the beta indicator for PMV Pharmaceuticals?

PMV Pharmaceuticals (PMVP) has a beta rating of 1.59. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the PMV Pharmaceuticals stock price target?

The target price for PMV Pharmaceuticals (PMVP) stock is $8.75, which is 388.83% above the current price of $1.79. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell PMV Pharmaceuticals stock

Buy or sell PMV Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing